UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

March 3, 2014

Date of Report (Date of earliest event reported)

NU SKIN ENTERPRISES, INC.

(Exact name of registrant as specified in its charter)

001-12421 (Commission File Number) 87-0565309

(IRS Employer Identification Number)

75 West Center Street Provo, UT 84601

(Address of principal executive offices and zip code)

(801) 345-1000

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) \square

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Delaware

(State or other jurisdiction of incorporation)

Item 2.02 Results of Operations and Financial Condition.

On March 3, 2014, Nu Skin Enterprises, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2013, and certain other information. A copy of the Company's press release is attached as Exhibit 99.1 to this report and incorporated by reference.

The information furnished pursuant to this Item 2.02 and the exhibit hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit.

99.1 Nu Skin Enterprises' press release dated March 3, 2014, regarding financial results for the fourth quarter and year ended December 31, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NU SKIN ENTERPRISES, INC. (Registrant)

/s/ Ritch N. Wood Ritch N. Wood Chief Financial Officer

Date: March 3, 2014

EXHIBIT INDEX

Exhibit No. Exhibit Description

99.1 Nu Skin Enterprises' press release dated March 3, 2014, regarding financial results for the fourth quarter and year ended December 31, 2013.



FOR IMMEDIATE RELEASE

CONTACTS: Investors — Scott Pond (801) 345-2657, <u>spond@nuskin.com</u> Media — Kara Schneck (801) 345-2116, <u>kschneck@nuskin.com</u>

NU SKIN ENTERPRISES REPORTS RECORD 2013 ANNUAL AND FOURTH-QUARTER RESULTS

PROVO, Utah — March 3, 2014 — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced record fourth-quarter results with revenue of \$1.056 billion, an 82 percent improvement over the prior-year period. Revenue was negatively impacted 4 percent by foreign currency fluctuations. Earnings per share for the quarter were \$2.02, a 108 percent year-over-year improvement.

The company reported full-year 2013 revenue of \$3.177 billion, a 49 percent year-over-year improvement. Annual revenue was negatively impacted 3 percent by foreign currency fluctuations. Earnings per share for the year were \$5.94, a 69 percent increase over 2012.

Recently, the company reclassified a small portion of selling expenses as a product rebate. This reclassification reduced fourth-quarter and annual revenue by approximately 1.8 percent and 1.9 percent, respectively, with a corresponding reduction of selling expenses. This reclassification had no impact on operating income, net income, earnings per share or cash flow, but resulted in slightly lower revenue than the company's previous estimate. The presentation of financial data for previous periods has been similarly reclassified for comparative purposes.

"We are pleased to report solid growth for the fourth quarter and full year of 2013," said Truman Hunt, president and chief executive officer. "We achieved this growth by continuing to increase our consumer base and sales force, while also executing the limited-time offering of our ageLOC TR90 weight management and body shaping system."

Regional Results

Greater China. In Greater China, fourth-quarter revenue increased 248 percent to \$481.6 million, compared to \$138.3 million in the prior-year period. Foreign currency fluctuations had a positive impact of 6 percent on the region's revenue. The sales leader count in the region improved 232 percent, while the number of actives increased 127 percent compared to the prior year.

North Asia. Fourth-quarter revenue in North Asia was \$286.3 million, compared to \$246.9 million for the same period in 2012. The region's results were negatively impacted approximately 8 percent by foreign currency fluctuations. The number of sales leaders in the region was up 14 percent and the number of actives improved 17 percent.

South Asia/Pacific. Revenue in South Asia/Pacific was \$99.5 million, a 57 percent increase compared to the prior year. Sales in the quarter were negatively impacted 11 percent by foreign currency fluctuations. The region's fourth-quarter sales leaders improved 60 percent while actives increased 22 percent compared to the same period in 2012.

Americas. Revenue in the Americas improved 59 percent to \$126.1 million, compared to \$79.1 million in the prior-year period. Foreign currency fluctuations negatively impacted sales in the region by 8 percent in the quarter. The number of sales leaders improved 30 percent while the number of actives increased 18 percent compared to the prior year.

Europe. Revenue in Europe was \$62.3 million, a 21 percent improvement over the prior-year period. Results in the region were positively impacted 5 percent by foreign currency fluctuations. Sales leaders in Europe decreased 1 percent while actives improved 3 percent compared to the prior year.

Operational Performance

The company's operating margin was 17.9 percent for the quarter, compared to 15.4 percent in the prior year. Operating margin for the year was 17.4 percent, up 140 basis points compared to 2012. Gross margin during the quarter was 84.4 percent, up 80 basis points over the prior-year period. Selling expenses, as a percent of revenue, were 48.2 percent in the fourth quarter, representing a 410 basis-point increase. The increase was driven by successful product launches and a higher number of sales leaders qualifying for promotional incentives. General and administrative expenses, as a percent of revenue, were 18.3 percent, improving 580 basis points over the prior year. Other income and expenses reflected a gain of \$3.4 million.

Nu Skin Enterprises, Inc. March 3, 2014 Page 3

The company's income tax rate for the quarter was 34.8 percent compared to 35.5 percent in the prior-year period. The company's cash and short-term investment position at the end of the quarter was \$547.1 million. Dividend payments during the quarter were \$17.6 million, and the company repurchased \$50.0 million of its outstanding shares, leaving \$395 million in the company's repurchase authorization at year end.

Annual Report

In response to recent media reports in China and the ensuing investigation by Chinese regulators, the company's audit committee recently began an internal review of the company's China operations. The company is unable at this time to predict the timing and outcome of the review. Given this review and the possibility that various components of its annual report on Form 10-K could be impacted, the company's board of directors has determined that it cannot file its annual report by the March 3rd due date. The company currently expects that the audit committee will have made sufficient progress in its review to enable the company to file its annual report by the March 18th extended filing deadline.

Outlook

"We remain optimistic about the potential of our business globally," said Hunt. "Our outlook for 2014, however, has been impacted by recent events that will negatively impact revenue this year.

"As previously announced, in China we have temporarily suspended all business promotional meetings as well as applications for new sales representatives. While these voluntary steps will negatively impact revenue and profitability in China in the short term, we believe these measures will enhance the likelihood of our long-term success in this important market.

"We are encouraged by the Chinese government's continuing commitment to develop its economy. We remain fully committed to working cooperatively with the government in China to ensure our operations are in compliance with the regulation of direct selling. We are diligently preparing to resume normal business activities as soon as possible, subject to resolution of the China regulatory review. In the meantime, we are taking steps to enhance our sales leader training processes following a period of rapid growth.

Nu Skin Enterprises, Inc. March 3, 2014 Page 4

"In addition, we continue to plan on regional LTOs of either our ageLOC TR90 system or ageLOC Tru Face Essence Ultra in all of our geographic regions during the year, and expect a positive impact to revenue from these LTOs and subsequent product roll-outs," concluded Hunt.

"For the first quarter of 2014 we now estimate revenue growth of 20 to 24 percent, or \$650 to \$670 million in revenue," stated Ritch Wood, chief financial officer. "We believe all of our regions are on track to show year-over-year revenue growth in the first quarter. The decrease in projected revenue versus our first-quarter guidance provided last November is primarily a result of the recent measures we have taken in China, slightly lower than anticipated revenue increases in other markets, and an anticipated impact of about \$20 million associated with the reclassification of a small percentage of selling expenses. In addition, our first-quarter revenue guidance anticipates a 4 percent negative impact from foreign currency fluctuations. Costs associated with China internal and external business reviews as well as lower than originally budgeted revenue will put pressure on our operating margin. We now project first-quarter earnings per share in the \$0.90 to \$0.94 range.

"We are early in the process of understanding the impact of recent events in China on our business, so it is difficult to project how reflective anticipated first quarter results will be of results for the remainder of the year. We believe we will be in a better position to provide specific updated annual guidance in conjunction with our first-quarter earnings release," concluded Wood.

The company's management will host a webcast with the investment community on March 3, 2014, at 11 a.m. EST. Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on Nu Skin Enterprises' website, http://ir.nuskin.com. An archive of the webcast will be available at this same URL through March 14, 2014.

About Nu Skin Enterprises, Inc.

Nu Skin Enterprises, Inc. demonstrates its tradition of innovation through its comprehensive anti-aging product portfolio, independent business opportunity and corporate social responsibility initiatives. The company's scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company. The company's anti-aging portfolio features the new ageLOC line of products including the ageLOC® TR90[™] weight management and body shaping system, ageLOC® R² nutritional supplement, and ageLOC® Transformation daily skin care system. A global direct selling company, Nu Skin operates in 53 markets worldwide and is traded on the New York Stock Exchange under the symbol 'NUS'. More information is available at http://www.nuskin.com.

Please Note: This press release, particularly the "Outlook" section, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, initiatives, strategies and new product introductions; statements of projections regarding revenue, operating margin, earnings per share, foreign currency impact and other financial items; statements of management's expectations underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

- risk that regulatory and media scrutiny and investigations in China, and any actions taken by the company or by regulators, could cause unanticipated delays or make it more difficult to forecast 2014 results, and could negatively impact the company's revenue and business in this market, including the interruption of sales activities, loss of licenses, and the imposition of fines, and any other adverse actions or events;
- risk that the company's internal review of its China operations could take longer than expected and that other events could cause the company to be unable to file the company's annual report on Form 10-K by March 18, 2014;
- any changes to the company's anticipated financial results for both the year and quarter ended December 31, 2013 set forth in this release, as a result of our independent registered public accounting firm completing its audit of the company's financial statements;
- any failure of current or planned initiatives or products to generate interest among our sales force and customers and generate sponsoring and selling activities on a sustained basis;
- risks associated with rapid growth globally, which could strain our ability to effectively manage our operations, and result in, among other things, product delays or shortages, operating mistakes and errors, inadequate customer service, inappropriate claims or promotions by our sales force, and governmental inquires and investigations, all of which could harm our revenue and ability to generate sustained growth and result in unanticipated expenses;

- risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, and increased risk of inventory write-offs if we over forecast demand for a product or change our planned initiatives or launch strategies;
- risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
- unpredictable economic conditions and events globally;
- regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;
- adverse publicity related to the company's business, products, industry or any legal actions or complaints by distributors or others;
- any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United States and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and
- continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

NU SKIN ENTERPRISES, INC. Consolidated Statements of Income (Unaudited) For the Fourth Quarters Ended December 31, 2013 and 2012 (in thousands, except per share amounts)

		2013	 2012
Revenue:			
Greater China	\$	481,561	\$ 138,322
North Asia		286,288	246,945
South Asia/Pacific		99,477	63,182
Americas		126,149	79,104
Europe		62,311	 51,641
Total revenue		1,055,786	579,194
Cost of sales		164,672	 95,044
Gross profit		891,114	 484,150
Operating expenses:			
Selling expenses		508,846	255,569
General and administrative expenses		193,673	 139,679
Total operating expenses	_	702,519	 395,248
Operating income		188,595	88,902
Other income, net		3,399	2,893
Income before provision for income taxes		191,994	 91,795
Provision for income taxes		66,723	 32,562
Net income	\$	125,271	\$ 59,233
Net income per share:			
Basic	\$	2.13	\$ 1.01
Diluted	\$	2.02	\$ 0.97
Weighted average common shares outstanding:			
Basic		58,791	58,620
Diluted		61,881	60,893

NU SKIN ENTERPRISES, INC. Consolidated Statements of Income (Unaudited) For the Years Ended December 31, 2013 and 2012 (in thousands, except per share amounts)

	 2013	 2012
Revenue: Greater China	\$ 1,363,182	\$ 550,690
North Asia South Asia/Pacific	869,400 378,988	785,302 328,597
Americas	370,988	285,283
Europe	 195,061	 182,385
Total revenue	3,176,718	2,132,257
Cost of sales	 505,806	 353,152
Gross profit	 2,670,912	 1,779,105
Operating expenses:		
Selling expenses	1,476,772	932,812
General and administrative expenses	 640,028	 505,449
Total operating expenses	 2,116,800	 1,438,261
Operating income	554,112	340,844
Other income, net	2,828	4,398
Income before provision for income taxes	 556,940	345,242
Provision for income taxes	 192,052	 123,597
Net income	\$ 364,888	\$ 221,645
Net income per share:		
Basic	\$ 6.23	\$ 3.66
Diluted	\$ 5.94	\$ 3.52
Weighted average common shares outstanding:		
Basic	58,606	60,600
Diluted	61,448	63,025

NU SKIN ENTERPRISES, INC. Consolidated Balance Sheets (Unaudited) As of December 31, 2013 and 2012 (in thousands)

		2013	 2012
ASSETS			
Current assets:			
Cash and cash equivalents	\$	525,153	\$ 320,025
Current investments		21,974	13,378
Accounts receivable		68,652	36,850
Inventories, net		339,669	135,874
Prepaid expenses and other		162,886	82,476
		1,118,334	588,603
Property and equipment, net		396,042	229,787
Goodwill		112,446	112,446
Other intangible assets, net		83,168	92,518
Other assets		111,072	 101,453
Total assets	\$	1,821,062	\$ 1,124,807
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current liabilities:			
Accounts payable	\$	82,684	\$ 47,882
Accrued expenses		626,284	233,202
Current portion of long-term debt		67,824	39,019
		776,792	 320,103
Long-term debt		113,852	154,963
Other liabilities		71,799	59,129
Total liabilities	_	962,443	 534,195
Stockholders' equity:			
Class A common stock		91	91
Additional paid-in capital		397,383	317,293
Treasury stock, at cost		(826,904)	(714,853)
Accumulated other comprehensive loss		(46,228)	(51,822)
Retained earnings		1,334,277	1,039,903
-		858,619	 590,612
Total liabilities and stockholders' equity	\$	1,821,062	\$ 1,124,807
		· · · ·	

NU SKIN ENTERPRISES, INC. Actives/Sales Leaders Statistics

	As of December 31, 2013		As of December 31, 2012		% Increase (Decrease)		
	Actives	Sales Leaders	Actives	Sales Leaders	Actives	Sales Leaders	
Greater China	490,000	61,546	216,000	18,527	126.9%	232.2%	
North Asia	409,000	19,816	349,000	17,395	17.2%	13.9%	
South Asia/Pacific	120,000	7,992	98,000	4,988	22.4%	60.2%	
Americas	193,000	8,274	164,000	6,352	17.7%	30.3%	
EMEA	123,000	4,489	119,000	4,528	3.4%	(0.9%)	
Total	1,335,000	102,117	946,000	51,790	41.1%	97.2%	

"Actives" are persons who purchased products directly from the company during the previous three months.

"Sales Leaders" include our independent distributors who have completed and who maintain specified sales requirements, and our sales employees and contractual sales promoters in China, who have completed certain qualification requirements.

###